Journal Information
Vol. 32. Issue 5.
Pages 280-285 (January 2008)
Vol. 32. Issue 5.
Pages 280-285 (January 2008)
Full text access
Bortezomib as an Alternative in the Treatment of Patients With Malignant Gammopathy
Bortezomib como alternativa en el tratamiento de pacientes con gammapatías malignas
Visits
2500
D. Lacruz Guzmána,
Corresponding author
dilagu1980@hotmail.com

Correspondence: Servicio de Farmacia. Hospital Santa María Rosell. Paseo Alfonso XIII, 6. 30203 Cartagena. Murcia. España.
, C. Funes Verab, M. Martínez Penellaa, M.J. Morales Laraa, V. Jorge Vidala, M.C. Mira Sirventa
a Servicio de Farmacia, Hospital Santa María Rosell, Cartagena, Murcia, Spain
b Servicio de Hematología, Hospital Santa María Rosell, Cartagena, Murcia, Spain
This item has received
Article information
Abstract
Objective

To describe the use of bortezomib in a district hospital as an alternative in the treatment of malignant gammopathy.

Methods

A retrospective analysis was carried out on patients treated with bortezomib in our hospital between November 2005 and October 2007. The patients’ medical histories were used to obtain data regarding diagnosis, treatments prior to bortezomib, date of the last disease progression, number of bortezomib courses, response to bortezomib, overall and event free survival, complications, and side effects.

Results

Forty-seven percent of the patients studied were male (5/12). The median age was 67, (range, 40-81). The main diagnosis was multiple myeloma on its own or associated with plasmocytoma. Bortezomib initiation coincided with the last disease progression in 83% of patients (10/12). Fifty percent of the patients completed 7-8 courses of bortezomib. Response was seen in 58% of the patients (7/12), partial response in 33% of them (4/12), and complete response in 25% (3/12). The most common adverse reactions were neuropathy and gastrointestinal toxicity which required treatment to be discontinued in 50% of cases.

Conclusions

According to the results obtained, bortezomib is a good alternative in the treatment of malignant gammopathy, above all in the case of plasmocytomas.

Key words:
Multiple myeloma
Bortezomib
Efficacy
Safety
Objetivo

Describir el uso de bortezomib en un hospital comarcal como alternativa en el tratamiento de gammapatías malignas.

Métodos

Análisis retrospectivo de los pacientes tratados con bortezomib en nuestro hospital desde noviembre de 2005 hasta octubre de 2007. A partir de la revisión de las historias clínicas de los pacientes se recogieron los datos correspondientes al diagnóstico, tratamientos previos a bortezomib, fecha de la última progresión de la enfermedad, número de ciclos de bortezomib, respuesta a éste, supervivencia global y libre de progresión, complicaciones y efectos secundarios.

Resultados

El 47% de los pacientes estudiados eran varones (5/12), con una mediana de edad de 67 años (rango, 40-81 años). El diagnóstico principal fue mieloma múltiple, solo o asociado a plasmocitoma.

El inicio con bortezomib coincidió con la última progresión de la enfermedad en el 83% de los pacientes (10/12). El 50% completó 7-8 ciclos con bortezomib. Se obtuvo respuesta en el 58% de los pacientes (7/12), alcanzándose criterios de respuesta parcial en el 33% (4/12) y respuesta completa en el 25% (3/12). Las reacciones adversas más frecuentes fueron neuropatía y toxicidad gastrointestinal, y supuso la suspensión del tratamiento en el 50% de los casos.

Conclusiones

Según los resultados obtenidos, bortezomib es una buena alternativa en el tratamiento de las gammapatías malignas, sobre todo en el caso de plasmocitomas.

Palabras clave:
Mieloma múltiple
Bortezomib
Eficacia
Seguridad
Full text is only available in PDF
References
[1.]
Fundación Leucemia y Linfoma. Libro blanco del mieloma múltiple en España 2004.
[2.]
Nacional Cancer Institute. United States: National Institute of Health. Mieloma múltiple y otras neoplasias de células plasmáticas (PDQ®): Tratamiento versión profesional de la salud (updated, Aug 11, 2007; accessed, 10 Dec 2007). Available from: http://www.cancer.gov/espanol/pdq/tratamiento/mieloma/HealthProfessional.
[3.]
J.A. Katzel, P. Hari, D.H. Vesole.
Multiple mieloma: charging toward a bright future.
CA Cancer J Clin, 57 (2007), pp. 301-318
[4.]
Ficha técnica de Velcade® (bortezomib). Laboratorio Jansen-Cilag.
[5.]
R.A. Kyle, V. Rajkumar, mieloma. Multiple.
N Engl J Med., 351 (2004), pp. 1860-1873
[6.]
M. Hughes, P. Micallef-Eynaud.
Bortezomib in relapsed multiple myeloma complicated by extramedullary plasmacytomas.
Clin Lab Haem., 28 (2006), pp. 267-269
[7.]
D.P. Finnegan, P. Kettle, M. Drake, C. Mattwes, H.D. Alexander, R. Popat, et al.
Bortezomib is effective in primary plasma cell leukaemia.
Leuk Lymphoma., 47 (2006), pp. 1670-1673
[8.]
O.A. O’Connor, J. Bright, C. Moskowitz, Phase II, et al.
clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-hogdking's Limphoma and mantle cell lymphoma.
J Clin Oncol., 23 (2005), pp. 676-684
[9.]
J. Sanz-Sabrafen, C. Besses Raebel, J.L. Vives Corrons.
Hematología clínica.
Elsevier, (2006),
[10.]
J. Bladé, D. Samson, D. Reece, J. Apperley, B. Björkstrand, G. Gahrton, et al.
criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation.
British Journal of Haematology., 102 (1998), pp. 1115-1123
[11.]
National Cancer Institute. United States: Cancer therapy evaluating program. Reporting guidelines. Common Terminology Criteria for Adverse Events v3.0 (updated, Sep 9, 2006; accessed, Dec 16, 2007). Available from: http://www.ctep.cancer.gov/reporting/ctc_v30.html
[12.]
P.G. Richardson, P. Sonneveld, M.W. Schuster, D. Irwin, E.A. Stadtmauer, T. Facon, et al.
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.
N Engl J Med., 352 (2005), pp. 2487-2498
[13.]
P.G. Richardson, B. Barlogie, J. Berenson, S. Singhal, S. Jagannath, D. Irwin, et al.
Aphase 2 study of bortezomib in relapsed, refractory myeloma.
N Engl J Med., 348 (2003), pp. 2609-2617
[14.]
Thalidomide (Drug Evaluation Monograph). In: Drugdex Information System. Micromedex Inc. Consulted, July 15, 2008.
[15.]
P. André, S. Cisternino, F. Chiadmi, A. Toledano, J. Schlatter, O. Fain, et al.
Stability of bortezomib 1-mg/mL solution in plastic syringe and glass vial.
The Annals of Pharmacotherapy., 39 (2005), pp. 1462-1466
[16.]
R. Manochakian, K.C. Miller, A.A. Chanan-Khan.
Clinical impact of bortezomib in frontline regimens for patients with multiple myeloma.
The Oncologist., 12 (2007), pp. 978-990
[17.]
M.V. Mateos, J.M. Hernández, M.T. Hernández, N.C. Gutiérrez, L. Palomera, M. Fuertes, et al.
Bortezomib plus melphalan and prednisone in ederly untreated patients with multiple myeloma: Results of a multicenter phase_study.
Blood., 108 (2006), pp. 2165-2172
[18.]
J.-L. Harousseau, M. Attal, X. Leleu, J. Troncy, B. Pegourie, A.M. Stoppa, et al.
Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: Results of an IFM phase II study.
Haematologica., 91 (2006), pp. 1498-1505
[19.]
H.E. Oakervee, R. Popat, N. Curry, P. Smith, C. Morris, M. Drake, et al.
PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma.
Br J Haematol., 129 (2005), pp. 755-762
[20.]
M. Wang, S. Giralt, K. Delasalle, B. Handy, R. Alexanian.
Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma: efficacy and neurotoxicity.
Hematology., 12 (2007), pp. 235-239
[21.]
M.A. Kosmo, R.P. Rale.
Plasma cell leukemia.
Semin Haematol, 24 (1987), pp. 202-208
[22.]
J. Blade, R.A. Kyle, Nonsecretory myeloma.
inmunoglobulin D myeloma, and plasma cell leukemia.
Haematol Oncol Clin North Am., 13 (1999), pp. 1259-1272
[23.]
J.K. Seok, K. Jeeyong, C. Yunjung, K.S. Bo, S.K. Byung.
Combination chemotherapy with bortezomib, cyclophosphamide and dexamethasone may be effective for plasma cell leukaemia.
Jpn J Clin Oncol., 37 (2007), pp. 382-384
[24.]
A. Esparís-Ogando, A. Alegre, B. Aguado, G. Mateo, N. Gutiérrez, J. Bladé, et al.
Bortezomib is an efficient agent in plasma cell leukemias.
Int J Cancer., 114 (2004), pp. 665-667
[25.]
C.S. Chim, G.C. Ooi, F. Loong, A.W. Au, A.K. Lie.
Side effects and good effects from new chemotherapeutics agents Case 3. Bortezomib in primary refractory plasmacytoma.
J Clin Oncol., 23 (2005), pp. 2426-2428
[26.]
M. Varettoni, S. Mangiacavalli, P. Zappasodi, G.M. Pica, M. Lazzarino, A. Corso.
Efficacy of bortezomib followed by local irradiation in two patients with extramedullary plasmacytomas.
Leuk Res., 32 (2008), pp. 839-841
[27.]
M.T. Krauth, A. Bankier, P. Valent, P. Kalhs, J. Drach.
Sustained remission including marked regression of paravertebral plasmacytoma in a patient with heavily pretreated, relapsed multiple myeloma after treatment with bortezomib.
Leuk Res., 29 (2005), pp. 1473-1477
[28.]
A. Nozza, L. Siracusano, A. Santoro.
Bortezomib-dexamethasona combination in a patient with refractory multiple myeloma and impaired renal function.
Clin Ther., 28 (2006), pp. 953-959
[29.]
A. Badros, O. Goloubeva, J.S. Dalal, I. Can, J. Thompson, A.P. Rapoport, et al.
Neurotoxicity of Bortezomib therapy in multiple myeloma: a singlecenter experience and review of the literature.
Cancer., 110 (2007), pp. 1042-1048
Copyright © 2008. Sociedad Española de Farmacia Hospitalaria
Download PDF
Idiomas
Farmacia Hospitalaria
Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.